Pharmafile Logo

transcreation

- PMLiVE

Looking Ahead: Transparency, Impact, and Instructional Design at CMEpalooza Spring 2025

Tomorrow at 2 PM ET, join Medscape for a thought-provoking Afternoon Snack Session at CMEpalooza Spring 2025, titled “Reverse Planning with Forward Thinking.” This session will spotlight how clear communication...

Medscape Education

- PMLiVE

Vaccines Are the Most Impactful Innovation in Health Equity

As deadly as the measles outbreak in west Texas and New Mexico is the spread of vaccine conspiracy theories and misinformation. According to KFF research from November 2024, childhood vaccination...

Medscape Education

- PMLiVE

NHS programme to give melanoma patients fast-track access to skin cancer vaccine

The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma

- PMLiVE

J&J’s subcutaneous Darzalex regimen approved by EC for newly diagnosed multiple myeloma

More than 35,000 people in the EU were diagnosed with the blood cancer in 2022

- PMLiVE

Amgen shares positive phase 3 results for Imdelltra in small cell lung cancer

The aggressive lung cancer accounts for approximately 15% of all lung cancer diagnoses

- PMLiVE

AstraZeneca’s Truqap recommended by NICE to treat advanced breast cancer

NICE estimates that around 1,100 patients will benefit from the twice-a-day tablet

- PMLiVE

BMS receives FDA approval for immunotherapy combination in liver cancer

Around 42,240 people are expected to be diagnosed with liver cancer in the US this year

- PMLiVE

Roche’s Columvi granted EC approval to treat diffuse large B-cell lymphoma

Approximately 38,000 people are diagnosed with DLBCL every year in Europe

- PMLiVE

How HCPs and patients are partnering to transform care

Equipping patients, carers and loved ones with the tools and understanding to make the choices that are right for them through shared decision-making

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links